Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

@article{Weiss2019SacituzumabGB,
  title={Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer},
  author={Jennifer A Weiss and A. Glode and W. Messersmith and J. Diamond},
  journal={Expert Review of Anticancer Therapy},
  year={2019},
  volume={19},
  pages={673 - 679}
}
ABSTRACT Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an… Expand
5 Citations

References

SHOWING 1-10 OF 49 REFERENCES
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
  • 144
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
  • T. Traina, K. Miller, +17 authors J. Cortés
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2018
  • 159
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
  • 113
An overview of triple-negative breast cancer
  • 162
  • Highly Influential
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
  • A. Bardia, I. Mayer, +19 authors L. Vahdat
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
  • 57
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
  • 447
  • PDF
Breast Cancer Immunotherapy: Facts and Hopes
  • L. Emens
  • Medicine
  • Clinical Cancer Research
  • 2017
  • 137
  • PDF
...
1
2
3
4
5
...